Symposium article. Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. M. J. Piccart

Size: px
Start display at page:

Download "Symposium article. Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. M. J. Piccart"

Transcription

1 Annals of Oncology 12 (Suppl. 1): S89-S94, Kluwer Academic Publishers. Printed in the Netherlands. Symposium article Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe M. J. Piccart Institut Jules Bordet, Brussels, Belgium Summary The human epidermal growth factor receptor-2 (HER2) is overexpressed/amplified in 20%-30% of human breast tumors and is a marker for a poor prognosis. For these reasons, HER2 has been selected as a therapeutic target for breast cancer treatment. Oncologists can no longer ignore the importance of HER2 status for treatment algorithms in breast cancer. In light of the consequences of HER2 status on treatment selection, further research is warranted to refine and standardize HER2 testing in order to minimize false-negative results and optimize selection of treatment pathways. The anti-her2 monoclonal antibody (MAb) trastuzumab (Herceptin) has proven valuable in treating HER2-positive, advanced-disease patients, and the availability of this novel biologic agent has important implications for clinical practice. This review describes a set of guidelines based on the current options for treatment of breast cancer. Two important factors have been taken into account in compiling these recommendations: (1) the lack of level I evidence to convincingly demonstrate the value of HER2 as a predictive marker for resistance or sensitivity to chemo- and hormonal therapy, and (2) the recently published pivotal phase II and III trial data proving the efficacy of trastuzumab as a single agent and in combination with chemotherapy in HER2-positive metastatic breast cancer. Key words: anti-her2 monoclonal antibody, HER2, Herceptin, predictive marker, prognostic marker, trastuzumab, treatment guidelines Introduction It is predicted that no further significant improvements in the survival of women with metastatic breast cancer are likely to result from the use of traditional chemotherapeutic agents, even in modified treatment regimens or combinations of the existing agents. The severe and often debilitating side effects accompanying chemotherapy also present an obstacle to the use of many cytotoxic agents [1]. Thus, there is an urgent need for novel treatment approaches that provide improved patient outcomes. The advances in drug development for breast cancer therapy over the past few decades have provided oncologists with a broader choice of treatments to offer patients with metastatic disease. In particular there has been increased emphasis on improved symptom control and quality of life, and a growing trend towards enhancing treatment individualization. Indeed, an area of active interest is the growing search for novel tumor or serum markers that may be of predictive significance for the individual patient. In addition to the powerful cytotoxic drugs, paclitaxel and docetaxel, which were introduced in the early 1990s, and other novel drug families such as the anti-metabolites and topoisomerase I inhibitors, considerable research efforts have been devoted to the development of new biologic therapies that specifically target the tyrosine kinase receptor-mediated signal transduction pathway. One such target is the human epidermal growth factor receptor-2 (HER2). HER2 is a tyrosine kinase membrane receptor [2] that, on activation, induces a phosphorylation cascade in cytoplasmic kinases (including ras and raf), leading to increased protein transcription and cellular growth [3]. A large amount of evidence has emerged to show that HER2 plays a central role in oncogenic transformation and tumorigenesis by interacting with the other members of the HER family to potentiate intracellular signaling [4-6]. HER2 plays a pivotal role in the biology of breast cancer. The HER2 proto-oncogene is overexpressed/ amplified in 20%-30% of breast cancers and HER2- positive tumors usually show more aggressive behavior [7, 8]. Of particular clinical significance is that overexpression/amplification of HER2 has been reported to be an independent prognostic factor in breast cancer patients [7, 8]. The involvement of the HER2 receptor in the pathogenesis of breast cancer and the link between HER2-positive status and poor prognosis first reported by Slamon and colleagues has been substantiated by numerous studies [9-16]. The occurrence of HER2 protein levels that are several orders of magnitude greater on the cell surface of HER2-positive cells compared with adjacent normal breast epithelium [12, 17, 18], combined

2 90 with the value of HER2 as a molecular marker to predict a reduced disease-free and overall survival, make this receptor an important potential therapeutic target in breast cancer. The potential impact of HER2 status on the planning of individualized treatment underscores the need to refine and standardize HER2 testing in order to minimize false-negative results. Currently, HER2 testing results are influenced by numerous factors, including the methods employed to determine HER2 status, as well as the antibodies and scoring systems used. Clearly, well-standardized assay systems and quality-control programs to assess whether individual laboratories can perform HER2 testing and scoring accurately and reproducibly are required. A novel treatment for HER2-positive patients An increased understanding of the biology of breast cancer over the past 30 years has led to the identification of a number of novel therapeutic approaches to anticancer treatment. In particular, the targeting properties of the immune system offer an approach to improve the selectivity of anti-cancer therapies. The humanized anti- HER2 monoclonal antibody (MAb) trastuzumab (Herceptin), which targets HER2 and activates the immune system to block the physiologic function of the HER2- signaling network [19], has been shown to have significant therapeutic value in HER2-positive metastatic breast cancer patients [20-23]. A phase II pivotal trial of 222 patients who had received extensive prior chemotherapy for metastatic disease indicated that trastuzumab monotherapy yielded a 15% response rate with a median duration of nine months [20]. Moreover, in a pivotal phase III trial of 469 patients, first-line therapy consisting of trastuzumab plus chemotherapy provided an approximate 25% increase in median survival in metastatic breast cancer patients compared with chemotherapy alone [21-23]. In both trials, trastuzumab was well tolerated with the only severe adverse effect being cardiotoxicity, which was, in most cases, transient and manageable. The availability of new anti-cancer agents such as anti-her2 MAbs means that clinicians now face the challenge of where and how to integrate novel biologic therapies into existing treatment algorithms. The emergence of the oncogene-targeted therapy, trastuzumab, has special impact on the treatment options available to HER2-positive breast cancer patients. Factors influencing treatment guidelines Another difficulty confronting clinicians is that the available data influencing the choice of therapy are by no means complete and are subject to change. In the provision of the treatment guidelines presented here, a number of important considerations have been taken into account. The first of these relates to the continued controversy surrounding the potential predictive value of HER2 with respect to response to classical forms of breast cancer therapy. Fundamentally, there is a distinct lack of level I evidence (defined as evidence obtained from meta-analysis of multiple, well-designed, controlled studies or from high-power randomized, controlled clinical trials) to convincingly demonstrate the value of HER2 as a predictive marker for response to hormonal therapy or chemotherapy. The guidelines presented here are, therefore, based on current and still limited understanding of the implications of HER2 overexpression/ amplification in breast cancer. Compared with the prognostic studies, the reports of therapy response prediction are fewer, involve smaller patient groups and have been generally less well controlled. Thus, while the data indicate that a HER2-positive status may correlate with increased resistance to certain hormone and/or chemotherapeutic agents, they do not enable any definitive conclusions to be made. A number of studies have indicated that HER2 may be a marker of reduced response to hormonal therapy in breast cancer [24-27]. Some reports have indicated that HER2-positive patients may be resistant to therapy with tamoxifen [28-32]. However, other studies have revealed no predictive value of HER2 with respect to hormonal therapy [33-36]. The available data to implicate HER2 in response to chemotherapy are even less convincing and are derived mainly from adjuvant studies [9, 37]. Studies on the predictive value of HER2 status in determining response to anthracycline-based chemotherapy have also yielded conflicting conclusions [38-43]. Of these, the Southwest Oncology Group (SWOG) 8814 trial results reported by Ravdin and colleagues [44] showed that there was no statistically significant benefit of chemoendocrine (tamoxifen + CAF [cyclophosphamide, doxorubicin, 5-fluorouracil (5-FU)]) vs. tamoxifen alone in HER2- negative patients, but that chemoendocrine therapy appeared to be superior to tamoxifen in HER2-positive patients. Another study demonstrated that anthracycline-based therapy was significantly more effective in HER2-positive compared with HER2-negative patients [45]. While these studies suggest that HER2 overexpression is of possible value in selecting patients who may particularly benefit from anthracycline-based therapy, all studies have inherent weaknesses, including their retrospective nature, incomplete retrieval of tumor blocks and lack of standardization of HER2 evaluation. This means that the results should be interpreted with caution. A major consideration in establishing where and how trastuzumab may fit into the current treatment guidelines for HER2-positive women are the phase II and III pivotal trial data of trastuzumab as a single agent and in combination with chemotherapy [20-23]. As second/ third-line monotherapy, trastuzumab provided durable tumor responses and was well tolerated [20]. When administered with chemotherapy (anthracyclines or paclitaxel) as first-line therapy in a pivotal phase III

3 91 Low Endocrine therapy]! ClosetoUow-upif HER2+ Risk evaluation ' Herceptin* if s (HER2+patient 1 \ Endocrine resistance refuses CT ' I Moderate, high ' Other agents ± H (1) 'Conservative' sequence in line with current labeling of H (2) Innovative sequence, worth testing m a clinical trial in view of the potential reduction in cardiotoxicity Other agents vinorelbine + 5-FU, CMF, capecitabine, 5-FU c I, liposomal doxorubtcin,?gemcrtabme CT. chemotherapy. A, anttiracyclme. T, taxane. H, Herceptin' Figure 1. Proposed pattern of systemic management in metastatic breast cancer patients. [Updated from ASCO Educational Book 1999.] trial, trastuzumab produced an approximate 25% increase in the median survival of HER2-positive metastatic breast cancer patients [21-23]. The safety data collected in both pivotal trials indicate that trastuzumab achieves selective therapeutic effects without the often severe toxicity caused by chemotherapy. This favorable safety profile has obvious implications on the individualization of patient treatments with respect to quality of life. Assessing prognosis and selecting treatment The first step to developing a systemic treatment plan for a patient with metastatic disease is to perform a risk evaluation (Figure 1). This involves assessing the extent of metastatic disease and determining whether there are sites of disease that require urgent treatment. The next question for the clinician to ask is whether the patient is likely to benefit from hormonal therapy. Key factors in deciding on whether to opt for hormonal therapy are hormone-receptor status, the length of disease-free interval and location of metastatic disease. Low risk If the patient falls into the low-risk category, characterized by positive hormone receptors, long disease-free interval (more than two years), a limited number of metastases, soft tissue, bone metastases, and no major involvement of vital organs, the preferred treatment option is endocrine therapy. It is felt that, whenever possible, hormonal therapy should be administered until resistance develops. In view of the relative weakness and conflicting nature of the current data on the effects of HER2 and the effectiveness of therapy with tamoxifen, it seems unwise to deny estrogen-receptor (ER)-positive, HER2-expressing patients the possible benefits offered by endocrine therapy. However, given the possible limited value of hormonal agents when HER2 is co-expressed with ER or progesterone receptors (PgR) [24, 25, 27], it is important to follow patient progress closely. If the patient has a disease that cannot be followed reliably, then this option should probably be disregarded, bearing in mind that time to disease progression for HER2- positive patients receiving endocrine therapy might be less than six months [46]. At the time endocrine resistance develops, the clinician switches to chemotherapy. In cases where the HER2-positive patient still has indolent disease and is concerned about the side effects associated with chemotherapy, it may be reasonable to provide single-agent trastuzumab. This recommendation is supported by the benefits of single-agent trastuzumab in HER2-positive metastatic breast cancer patients observed in a pivotal phase II trial [20]. There are also promising data emerging from a phase II dose-response study of single-agent trastuzumab as first-line treatment in HER2-positive metastatic breast cancer patients without prior chemotherapy for stage IV disease [47]. In this trial, patients whose tumors are strongly HER2-positive (3+ by immunohistochemistry) achieve a response rate of 35%. For this reason, a high priority for clinical investigation is a randomized trial comparing first-line trastuzumab as a single agent followed by chemotherapy at the time of progression with first-line trastuzumab combined with chemotherapy. If the former strategy does not compromise survival benefit, it has the advantage of delaying chemotherapy by several months in responding patients. Moderate or high risk If evaluation of the patient reveals a moderate or high risk, characterized by negative hormone receptors, short disease-free interval (less than two years), extensive and/or visceral metastases, and vital organ involvement but no major organ dysfunction, chemotherapy is indicated. Knowledge of HER2 status and subgroup (i.e., IHC 1+, 2+ or 3+) is essential in the context of choosing whether to provide trastuzumab therapy; so far, benefit has been demonstrated for the HER2-positive 2+ and 3+ population as a whole, with subset analyses suggesting that the 3+ subgroup derives the greatest benefit. Treatment preferences are also influenced by the type of therapy administered in the adjuvant setting. In the case of previous anthracycline exposure, which applies to many patients nowadays, the current best option appears to be the combination of trastuzumab with a taxane. The pivotal phase III trial data support the use of paclitaxel with trastuzumab: addition of trastuzumab to paclitaxel significantly increased survival, and improved the response rate from 17% to 41% and median response duration from 4.5 to 10.5 months, compared with paclitaxel alone. To assess the efficacy of trastuzumab with a taxane other than paclitaxel, a phase II trial of trastuzumab plus docetaxel asfirst-linetherapy in HER2-positive metastatic breast cancer patients is underway and results are expected in In the absence of prior anthracycline exposure, which

4 92 is uncommon today, the best treatment sequence remains to be denned. The first option is doxorubicin-cyclophosphamide (AC) followed, at progression, by taxane plus trastuzumab. This option is considered to be the conservative route. Although all the published studies suggest that, with adequate anthracycline doses, HER2-positive patients do relatively well with anthracycline-based treatment [44, 45, 48, 49], there may be some problems with delaying the use of trastuzumab until the time of progression. Firstly, the survival advantage seen in the phase III pivotal trial was associated with the use of trastuzumab upfront [22, 23]. Secondly, delaying the use of trastuzumab after prior AC may not be optimal, given the potential increased risk for cardiotoxicity. In the phase III combination trial, a higher incidence of cardiac dysfunction was observed in the trastuzumab plus AC group. In addition, the potentially short interval between AC and taxane plus trastuzumab in the conservative route calls for stringent cardiac monitoring. The preferred route might be taxane plus trastuzumab used initially, which can be followed by anthracyclines at the time of progression. This approach is worth exploring as a strategy potentially associated with a reduced cardiac risk and offering the clear advantage of early tarstuzumab use. If the data from recently closed phase III trials show anthracycline/taxane regimens to be associated with survival prolongation compared with AC, then the sequence AT (doxorubicin plus taxane) followed by trastuzumab at the time of progression would need to be tested. In any event, the relatively poor prognosis of HER2- positive patients should motivate their clinicians to offer them participation in prospective clinical trials, which will explore a number of important issues, including the potential value of other trastuzumab-chemotherapy combinations, e.g., vinorelbine/5-fu ± trastuzumab, cyclophosphamide/methotrexate/5-fu ± trastuzumab. The results of ongoing phase II/III trials are eagerly awaited. Treatment guidelines can change rapidly The recommendations presented in Figure 1 have been updated since we last published guidelines for integration of new therapies into the breast cancer treatment algorithm [1]. In this context, it is important to appreciate that treatment guidelines can change completely within as little as six months. The positive results from the pivotal phase II and III trials have prompted numerous trials of trastuzumab either alone or in combination with chemotherapy. A phase II study has been conducted of weekly trastuzumab plus paclitaxel in HER2-positive and -negative patients with metastatic breast cancer [50]. A phase II study is underway to assess the safety and efficacy of trastuzumab in combination with vinorelbine as second- or third-line therapy for HER2-positive, metastatic breast cancer [51]. A relatively small phase II study is ongoing to investigate the combination of trastuzumab plus docetaxel in HER2-positive patients with metastatic breast cancer [52]. Future trials are expected to include trastuzumab in combination with other single agents such as docetaxel and aromatase inhibitors, and a trial to compare cardiotoxicity associated with epirubicin/cyclophosphamide (EC) plus trastuzumab (in HER2-positive patients) vs. EC alone (in HER2-negative patients). The accumulation of new trial data will lead to the expansion and likely revision of the treatment guidelines presented here. In addition, some guidelines should be accepted with caution as recommendations for certain treatment options await additional data from clinical trials regarding safety and/or efficacy. Conclusions The evidence to support HER2 as an important biologic marker in metastatic breast cancer, and the availability of a new and effective therapy targeting HER2, means that oncologists should view HER2 status as an important factor when choosing treatment programs for breast cancer patients. Despite the recognized significance of the HER2 receptor in the pathogenesis and prognosis of breast cancer, there is a need to standardize testing methods in order to provide accurate and reproducible testing results. The anti-her2 MAb trastuzumab offers clear therapeutic benefits to HER2-positive patients. The reported activity and safety of trastuzumab, both alone and in combination with non-anthracycline-based chemotherapy, have important implications for current treatment guidelines. This novel biologic agent represents an attractive therapeutic option on account of its significant survival benefit in combination with chemotherapy. The available data indicate that trastuzumab is most beneficial when used initially; delaying the use of trastuzumab may preclude the survival benefits observed in the phase III clinical trial. Further exploration of the potential therapeutic efficacy of anti-her2 MAbs in combination with a variety of new and classic anticancer agents is likely to further improve outcomes in metastatic breast cancer, thereby influencing the treatment algorithms governing the management of breast cancer. Acknowledgement With thanks to the Jean-Claude Heuson Foundation for their continuous support for breast cancer research at the Jules Bordet Cancer Institute. Note Dr Piccart has reported that she is a consultant for Roche and Genentech, Inc., and has received research support from Roche.

5 93 References 1. Piccart M, Awada A, Hamilton A. Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. Am Soc Clin Oncol 1999; 35th Annual Meeting, May 15-18, Atlanta, Georgia. Educational Book: Coussens L, Yang-Feng TL, Liao Y-C et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: Hung M-C, Lau Y-K. Basic science of HER-2/neu: A review. Semin Oncol 1999; 26 (Suppl 12): Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: Graus-Porta D, Beerli RR, Daly JM et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: Tzahar E, Waterman H, Chen X et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Moll Cell Biol 1996; 16: Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989; Allred DC, Clark GM, Tandon AK et al. HER-2/neu in nodenegative breast cancer- Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: Borg A, Tandon AK, Sigurdsson H et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; Borg A, Baldetorp B, Ferno M et al. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6: Hynes NE. Amplification and overexpression of the erbb-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993; 4: Hynes NE, Stern DF. The biology of erbb-2/neu/her-2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1994; 1198: King CR, Kraus MH, Aaronsen SA. Amplification of a novel c-erbb-related gene in a human mammary carcinoma. Science 1985; 229: Press MF, Pike MC, Hung G et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: Correlation with poor prognosis. Cancer Res 1994; 54: Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: Hynes NE, Gerber HA, Saurer S et al. Overexpression of the c-erbb-2 protein in human breast tumor cell lines. J Cell Biochem 1989; 39: Lewis GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-pl85 HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: Weiner LM. An overview of monoclonal antibody therapy of cancer Semin Oncol 1999; 26: Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-her2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: Eiermann W, on behalf of the International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001: 12 (Suppl 1). S57-S62 (this supplement). 22. Norton L, Slamon D, Leyland-Jones B et al. Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999; 18: 127a (Abstr 483). 23. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin (humanized anti-her2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17: 98a (Abstr 377). 24. Berns EMJJ, Foekens JA, van Staveren IL et al. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 1995; 159: Leitzel K, Teramoto Y, Konrad K et al. Elevated serum c-erb-b2 levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: Plunkett TA, Houston SJ, Tubens RD et al. c-erb-b2 is a marker of resistance to endocrine therapy in advanced breast cancer. Proc Am Soc Clin Oncol 1998; 17: 103a (Abstr 397). 27. Yamauchi H, O'Neil A, Gelman R et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: Bianco AR, De Laurentis M, Carlomagno C et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbb2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998; 17: 97a (Abstr 373). 29. Giai M, Roagna R, Ponzone R et al. Prognostic and predictive relevance of c-erb-b2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994; 14: Khjn JG, Berns EM, Bontenbal M et al. Cell biological factors associated with response of breast cancer to systemic treatment. Cancer Treat Rev 1993; 19 (Suppl): Newby JC, Johnston RD, Smith IE et al. Expression of epidermal growth factor receptor and c-erbb2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3: Wright C, Nicholson S, Angus B et al. Relationship between c-erb-b2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: Archer SG, Eliopoulos A, Spandidos D et al. Expression of ras p21, p43 and HER2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72: Elledge RM, Green S, Ciocca D et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study. Clin Cancer Res 1998; 4: Berry DA, Muss HB, Thor AD et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18: Hamilton A, Piccart MJ. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000; 11: Gusterson BA, Gelber RD, Goldhirsch KN et al. Prognostic importance of c-erbb-2 expression in breast cancer. J Clin Oncol 1992; 10: AH IU, Campbell G, Lidereau R et al. Lack of evidence for the prognostic significance of c-erbb-2 amplification in human breast cancer. Oncogene Res 1988; 3: Clahsen PC, van de Velde CJ, Duval C et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: Niskanen E, Blomqvist C, Franssila K et al. Predictive value of c-erbb-2, p53, cathepsin-d and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997; 76:

6 Ravdin PM Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999, 26: Rozan S, Vincent-Salomon A, Zafrani B et al. No significant predictive value of c-erbb-2 orp53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: Untch M, Thomssen C, Kahlert D et al. Lack of c-erb-b2 overexpression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer. San Antonio Breast Cancer Conference, December 1998 (Abstr 110). 44. Ravdin PM, Green S, Albain KS et al. Initial report of the SWOG biological correlative study of c-erb-b2 expression as a predictor of outcome in a trial comparing adjuvant CAF Twith tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998; 17: 97a (Abstr 374). 45. Paik S, Bryant J, Park C et al. erbb-2 and response to doxorubicin in patients with axillary node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: Houston SJ, Plunkett TA, Barnes DM et al. Overexpression of c-erbb2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79: Vogel C, Cobleigh M, Tripathy D et al. First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-her2 antibody). Proc Am Soc Clin Oncol 2000; 19: 71a (Abstr 275). 48. Muss HB, Thor AD, Berry DA et al. c-erbb-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: Thor AD, Berry DA, Budman DR et al. erbb-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: Esteva FJ, Seidman AD, Fornier M. Analysis of response to weekly 1 H Taxol (T) plus Herceptin (H) by immunophenotypic analysis in HER-2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer. San Antonio Breast Cancer Symposium, 8-11 December 1999 (Abstr 17) 51. Burstein HJ, Kuter I, Richardson PG et al. Herceptin (H) and vinorelbine (V) as second-line therapy for HER2-positive metastatic breast cancer (MBC): A phase II study. San Antonio Breast Cancer Symposium, 8-11 December 1999 (Abstr 18). 52. Burris HA, Jainesworth JD, Albain K et al. Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2. Book of abstracts, ECCO 10 Conference, September 1999 (Abstr 1293). Correspondence to: M. J. Piccart, MD, PhD Institut Jules Bordet Centre des Tumeurs de L'ULB Chemotherapy Department Rue Heger-Bordet Brussels Belgium martine.piccart@bordet.be

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive

More information

Miquel Àngel Seguí Palmer

Miquel Àngel Seguí Palmer Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

One of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.

One of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen. Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a

More information

Cellular, Molecular, and Biochemical Targets in Breast Cancer

Cellular, Molecular, and Biochemical Targets in Breast Cancer Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm

More information

Breast Cancer Educational Program. June 5-6, 2015

Breast Cancer Educational Program. June 5-6, 2015 Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

HER2 Testing in Breast Cancer

HER2 Testing in Breast Cancer HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor

More information

Clinical trials of Herceptin 1 (trastuzumab)

Clinical trials of Herceptin 1 (trastuzumab) European Journal of Cancer 37 (2001) S18±S24 www.ejconline.com Clinical trials of Herceptin 1 (trastuzumab) J. Baselga * Department of Medical Oncology, Hospital General Universitari Vall d'hebron, Psg.

More information

Adjuvant treatment of breast cancer patients with trastuzumab

Adjuvant treatment of breast cancer patients with trastuzumab doi:10.2478/v10019-007-0020-y review Adjuvant treatment of breast cancer patients with trastuzumab Erika Matos, Tanja Čufer Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia

More information

Positività per HER-2 nei carcinomi subcentimetrici

Positività per HER-2 nei carcinomi subcentimetrici Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects

More information

Optimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient

Optimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient Optimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient Stefan Glück, Carlos L. Arteaga, and Kent Osborne, University of Miami s Sylvester Comprehensive Cancer Center,

More information

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based

More information

Abstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2

Abstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2 Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo

More information

Adjuvant Therapy with Trastuzumab

Adjuvant Therapy with Trastuzumab Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products

More information

London Cancer New Drugs Group APC/DTC Briefing

London Cancer New Drugs Group APC/DTC Briefing London Cancer New Drugs Group APC/DTC Briefing Continued use of trastuzumab following disease progression in metastatic breast cancer Contents Summary 1 Background 2 Adverse events/safety issues Health

More information

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Recommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality

Recommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline

More information

J Clin Oncol 22:3700-3704. 2004 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 22:3700-3704. 2004 by American Society of Clinical Oncology INTRODUCTION VOLUME 22 NUMBER 18 SEPTEMBER 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in With Breast Cancer in

More information

HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays

HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays O R I G I N A L A R T I C L E HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays TK Yau H Sze Inda S Soong F Hioe

More information

Trastuzumab Use in Breast Cancer: Clinical Issues

Trastuzumab Use in Breast Cancer: Clinical Issues Trastuzumab can be beneficial when used alone or with cytotoxic antitumor agents in selected patients with breast cancer. James Rosenquist. Tampa-New York 1188, 1975. Lithograph, 36 74. Courtesy of Graphicstudio/USF.

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

What is the optimal sequence of anti-her2 therapy in metastatic breast cancer?

What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival

More information

PATHOLOGY. HercepTestTM. Product Information

PATHOLOGY. HercepTestTM. Product Information PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying

More information

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015 Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER

LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER 146 Experimental Oncology 37, 146 150, 2015 (June) Exp Oncol 2015 37, 2, 146 150 LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER J. Zekri 1, 2, M. Mokhtar 3, S.M.

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression

A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression September 27, 2011 James A. Joyce Chairman & CEO, Aethlon Medical, Inc jj@aethlonmedical.com Last week, we introduced HER2osome as a

More information

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness

More information

J Clin Oncol 24:3032-3038. 2006 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24:3032-3038. 2006 by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study JBUON 2013; 18(2): 314-320 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective

More information

Strength of Study End Point(s): Progression-free survival

Strength of Study End Point(s): Progression-free survival AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and

More information

TECHNICAL INSIGHTS TECHNOLOGY ALERT

TECHNICAL INSIGHTS TECHNOLOGY ALERT TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

PI3K signaling pathway a new target for breast cancer treatment

PI3K signaling pathway a new target for breast cancer treatment PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as

More information

Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer

Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer Review Article [1] March 02, 1998 By Harold A. Harvey, MD [2] The new generation of potent steroidal and nonsteroidal inhibitors

More information

Breast Cancer Treatment Guidelines

Breast Cancer Treatment Guidelines Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision

More information

Metastatic Breast Cancer...

Metastatic Breast Cancer... DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a

More information

Measurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center

Measurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center Measurement of HER2 Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center Trastuzumab Metastatic Adjuvant Lapatinib Metastatic Trials Why Test

More information

Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials

Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric

More information

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

HER2 Status: What is the Difference Between Breast and Gastric Cancer? Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC

More information

Pharmacogenetic Activities in SWOG Breast Cancer

Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose

More information

The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment

The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment Ahmad Awada, MD, PhD Head of Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles

More information

Adjuvant Therapy for Breast Cancer: Questions and Answers

Adjuvant Therapy for Breast Cancer: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast

More information

3. Chemotherapy. "Practice Guidelines for Breast Cancer" Research. Questions. NCCN/JCCNB Seminar in Japan January 13-14, 2007 January 26-27, 2008

3. Chemotherapy. Practice Guidelines for Breast Cancer Research. Questions. NCCN/JCCNB Seminar in Japan January 13-14, 2007 January 26-27, 2008 NCCN/JCCNB Seminar in January 13-14, 2007 January 26-27, 2008 "Practice Guidelines for Breast Cancer" A Comparison between and (: as of 2007, : according to "Practice Guideline for Breast Cancer"(2005)

More information

Oncologist. The. Breast Cancer

Oncologist. The. Breast Cancer The Oncologist Breast Cancer Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors STEFANIA GORI, a SIMONETTA

More information

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women

More information

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

More information

Biomarker Trends in Breast Cancer Research

Biomarker Trends in Breast Cancer Research WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that

More information

What s New With HER2?

What s New With HER2? What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston

More information

The Impact of Taxotere on Adjuvant Breast Cancer

The Impact of Taxotere on Adjuvant Breast Cancer The Impact of Taxotere on Adjuvant Breast Cancer a report by Pierre Fumoleau and Henri Roché Centre Georges François Leclerc, Dijon, and Institut Claudius Regaud, Toulouse, France DOI: 10.17925/EOH.2005.0.0.1l

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Phase III trials in oncology

Phase III trials in oncology Phase III trials in oncology Setting standards of care? Siegfried Seeber and Ada H Braun* Survival data from phase III trials can be very misleading because patients are not offered the best follow-up

More information

Inteligentaj decidoj... Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms. Intelligent Questions?

Inteligentaj decidoj... Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms. Intelligent Questions? Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms Stefan Aebi Universitätsspital Bern, Inselspital Klinik für Medizinische Onkologie und Brust /Tumorzentrum der Frauenklinik Inteligentaj

More information

Breast Cancer - Adjuvant and Metastatic

Breast Cancer - Adjuvant and Metastatic Breast Cancer Update Live Clinical Investigator Think Tank: Proceedings from a CME Satellite Symposium at the Breast Cancer Symposium in San Francisco, California EDITOR A ND MODER ATOR Neil Love, MD FACULT

More information

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer $

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer $ The Breast (2004) 13, 173 183 THE BREAST www.elsevier.com/locate/breast ORIGINAL ARTICLE Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer $ T.M.

More information

I will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too?

I will be having surgery and radiation treatment for breast cancer. Do I need drug treatment too? What is node-positive breast cancer? Node-positive breast cancer means that cancer cells from the tumour in the breast have been found in the lymph nodes (sometimes called glands ) in the armpit area.

More information

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic

More information

Targeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University

Targeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University Targeted Therapy in an Era of Genomic Medicine George W. Sledge MD Stanford University Why Do Women Die of Breast Cancer? Bad biology Avoidable deaths Important subsets of breast cancers defined by molecular

More information

Trastuzumab (Herceptin ) for patients with metastatic breast cancer

Trastuzumab (Herceptin ) for patients with metastatic breast cancer JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand

More information

MEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14

MEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14 MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,

More information

Complimentary CME. Metastatic Breast Cancer: Monitoring Soluble HER2 Levels

Complimentary CME. Metastatic Breast Cancer: Monitoring Soluble HER2 Levels Complimentary CME Metastatic Breast Cancer: Monitoring Soluble HER2 Levels Program Description HER2/neu-positive tumors account for approximately 20% of all breast cancers and these tumors carry poor prognosis.

More information

AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY

AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania

Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal

More information

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY

More information

Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies

Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies Annals of Oncology 15 (Supplement 4): iv23 iv29, 2004 doi:10.1093/annonc/mdh901 Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies V. D Hondt & M. Piccart

More information

I. THE IMPORTANCE OF HER2 IN BREAST CANCER

I. THE IMPORTANCE OF HER2 IN BREAST CANCER I. THE IMPORTANCE OF HER2 IN BREAST CANCER The human epidermal growth factor receptors (HER), also known as ERBB receptors, are a family of signal transduction proteins. There are 4 family members in humans

More information

Effect of Chemotherapy for Luminal A Breast Cancer

Effect of Chemotherapy for Luminal A Breast Cancer Yonago Acta medica 2013;56:51 56 Original Article Effect of Chemotherapy for Luminal A Breast Cancer Naotaka Uchida,* Takako Suda and Kiyosuke Ishiguro *Clinic of Surgery, Tottori Prefectural Kosei Hospital,

More information

New Approval Mechanism for Breast Cancer using pathologic Complete Response

New Approval Mechanism for Breast Cancer using pathologic Complete Response New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine

More information

Florida Breast Health Specialists Breast Cancer Information and Facts

Florida Breast Health Specialists Breast Cancer Information and Facts Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Nancy E. Davidson, MD Johns Hopkins University. Breast Cancer

Nancy E. Davidson, MD Johns Hopkins University. Breast Cancer This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Proportion of patients with invasive breast cancer in whom ER, PR and/or

Proportion of patients with invasive breast cancer in whom ER, PR and/or 1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment

More information

5.04.20. Perjeta. Perjeta (pertuzumab) Description

5.04.20. Perjeta. Perjeta (pertuzumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)

More information

Esin Oktay, Özlem Yersal, Nezih Meydan, Mehmet SaLJroLlu, Ömer UyanJk, andsabribarutca. 1. Introduction. 2. Case Presentation

Esin Oktay, Özlem Yersal, Nezih Meydan, Mehmet SaLJroLlu, Ömer UyanJk, andsabribarutca. 1. Introduction. 2. Case Presentation Case Reports in Oncological Medicine Volume 2013, Article ID 234391, 4 pages http://dx.doi.org/10.1155/2013/234391 Case Report Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast

More information

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 5-year survival: an overview of the randomised trials Early Breast Cancer Trialists Collaborative Group (EBCTCG)*

More information

Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer

Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer CLINICAL PRACTICE GUIDELINE www.asco.org/guidelines/treather2pos American Society of Clinical Oncology. All rights reserved. Introduction

More information

Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles

Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor

More information